KUWAIT DRUGS

 

SEARCH

 

SUGGESTIONS

 

ADD PRODUCTS

 

HOME

0-9    A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

 

 

PREVIOUS

  

NEXT

 
 

DICLOMAX 50 MG TABLETS

 

 
 

 

GENERIC NAMES

MANUFACTURERS 

MEDICAL GROUP

MEDICAL ARTICLES

 

DRUGS IN :

 

 

FDA DRUGS

UNITED STATES

CANADA

UNITED KINGDOM

AUSTRALIA

GERMANY

FRANCE

MIDDLE EAST

KUWAIT

LEBANON

EGYPT

SYRIA

BAHRAIN

IRAN

JORDAN

SAUDI ARABIA

UNITED ARAB EMIRATES

 

 

 
 

SIZE:

50 MG

 

GENERIC NAME:

DICLOFENAC

 

MANUFACTURER:

JAZEERA PHARM. IND

 

UNIT:

 

ADMINISTRATION ROUTE:

 

FDA PREGNANCY GROUP:

B

 

INDICATIONS:

Ankylosing spondylitis

Arthritis, osteoarthritis

Arthritis, rheumatoid

Dysmenorrhea

Inflammation, opthalamic, postoperative

Keratosis, actinic

Pain, mild to moderate

Pain, ophthalmic

Photophobia, postoperative

 

SIDE EFFECTS:

aplastic anemia

aseptic meningitis

azotemia

blurred vision

confusion

conjunctivitis

constipation

corneal edema

corneal erosion

diarrhea

dizziness

dyspepsia

dysphagia

elevated hepatic enzymes

erythema multiforme

esophageal stricture

esophageal ulceration

esophagitis

fluid retention

gastritis

GI bleeding

GI perforation

headache

heart failure

hematuria

hemolytic anemia

hepatic necrosis

hepatitis

infection

interstitial nephritis

iritis

jaundice

keratitis

melena

nausea/vomiting

nephrotic syndrome

ocular irritation

ocular pain

odynophagia

pancreatitis

pancytopenia

peptic ulcer

peripheral edema

photophobia

platelet dysfunction

porphyria

proteinuria

pruritus

purpura

pyrosis (heartburn)

renal failure (unspecified)

renal papillary necrosis

Stevens-Johnson syndrome

tinnitus

urticaria

visual impairment

xerophthalmia

abdominal pain

acute generalized exanthematous pustulosis (AGEP)

agranulocytosis

anaphylactoid reactions

anemia

 

ABSOLUTE CONTRAINDICATIONS :

 

RELATIVE CONTRAINDICATIONS :

acute bronchospasm

alcoholism

anemia

anticoagulant therapy

asthma

benzyl alcohol hypersensitivity

breast-feeding

chemotherapy

children

coagulopathy

contact lenses

corticosteroid therapy

dehydration

dental disease

dental work

diabetes mellitus

edema

elderly

exfoliative dermatitis

GI bleeding

GI disease

heart failure

hemophilia

hepatic disease

hypertension

hypovolemia

immunosuppression

jaundice

labor

nasal polyps

neutropenia

ocular exposure

ocular surgery

peptic ulcer disease

porphyria

pregnancy

renal disease

renal failure

renal impairment

rheumatoid arthritis

skin abrasion

sunlight (UV) exposure

surgery

systemic lupus erythematosus (SLE)

thrombocytopenia

tobacco smoking

ulcerative colitis

 

ADULT DOSE:

Analgesic and Antidysmenorrheal-Oral, 50 mg three times a day as needed. If necessary, 100 mg may be administered for the first dose only. Rheumatoid arthritis-Oral, 150 to 200 mg per day in three or four divided doses, initially. After a satisfactory response has been obtained, dosage should be reduced to the minimum dose that provides continuing control of symptoms, usually 75 to 100 mg a day in three divided doses. Osteoarthritis- Oral, 100 to 150 mg per day in two or three divided doses, initially. After a satisfactory response has been obtained, dosage should be reduced to the minimum dose that provides continuing control of symptoms. Ankylosing spondylitis - Oral, 100 to 125 mg a day in four or five divided doses, initially. After a satisfactory response has been obtained, dosage should be reduced to the minimum dose that provides continuing control of symptoms.

 

MAXIMUM ADULT DOSE:

Analgesic and Antidysmenorrheal-Up to 200 mg on the first day, then 150 mg per day thereafter. Rheumatoid arthritis- 225 mg per day. Osteoarthritis- 150 mg per day; higher doses have not been studied.

 

PEDIATRIC DOSE:

Safety and efficacy have not been established.  

 

MAXIMUM PEDIATRIC DOSE:

 

ELDERLY DOSE:

 

 

PREVIOUS

  

NEXT